Theodore W Clark

US Patent:

20120129217, May 24, 2012

Filed:

Sep 20, 2011

Appl. No.:

13/237653

Inventors:

Paul Colussi - Gloucester MA, US
Theodore G. Clark - Ithaca NY, US

International Classification:

C12P 21/00
C12N 1/11
C12N 15/79

US Classification:

435 691, 4353201, 4352581

Abstract:

This invention is directed to methods for recombinant polypeptide production and, in particular, methods and products for the production of recombinant polypeptides in ciliates.

US Patent:

20190144538, May 16, 2019

Filed:

May 2, 2017

Appl. No.:

16/098670

Inventors:

- Arlington MA, US
Janna Bednenko - Woburn MA, US
Yelena Bisharyan - Arlington MA, US
Ashot Papoyan - Arlington MA, US
Joanna Cardarelli - Charlestown MA, US
Theodore G. Clark - Ithaca NY, US
Douglas Kahn - Boston MA, US
Lore Mariën - Gent, BE
Bas Van Der Woning - Bachte-Maria-Leerne, NL
Hans De Haard - Oudelande, NL
William D. Harriman - Alameda CA, US
Ellen J. Collarini - Oakland CA, US

Assignee:

Tetragenetics, Inc. - Arlington MA

International Classification:

C07K 16/28
C07K 16/44
A61P 37/06

Abstract:

Anti-Kv1.3 antibodies (mAbs), particularly mAbs that specifically bind to Kv1.3 with high affinity and/or inhibit Kv1.3 function, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-Kv1.3 mAbs are provided. Additionally, canonical structures for CDRs in the VH and VL regions of anti-Kv1.3 antibodies are provided. The disclosure also provides nucleic acid molecules encoding the anti-Kv1.3 mAbs, expression vectors, host cells, methods for making the anti-Kv1.3 mAbs, and methods for expressing the anti-Kv1.3 mAbs. Finally, methods of using the anti-Kv1.3 mAbs as therapeutics, such as for preventing or treating an autoimmune disorder, are disclosed.